Review of randomised trials analyses cardiovascular benefits and risks of GLP-1 receptor agonists in people with type 2 diabetes
GLP-1 receptor agonists reduced the risk of worsening kidney function in patients with type 2 diabetes, an analysis of randomised trials has found. The study, Cardiovascular, mortality, and ...